RESEARCH ARTICLE

Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya [version 1; peer review: 2 approved, 1 approved with reservations]

Hellen C. Barsosio\(^1,2\), John N. Gitonga\(^1\), Henry K. Karanja\(^1\), Doris K. Nyamwaya\(^1\), Donwilliams O. Omuoyo\(^1\), Everlyn Kamau\(^1\), Mainga M. Hamaluba\(^1\), Joyce U. Nyiro\(^1\), Barnes S. Kitsao\(^1\), Amek Nyaguara\(^1\), Stella Mwakio\(^1\), Charles R. Newton\(^1,3\), Rosemary Sang\(^4\), Daniel Wright\(^1,5\), Eduard J. Sanders\(^1\), Anna C. Seale\(^1,6\), Charles N. Agoti\(^1\), James A. Berkley\(^1,7\), Philip Bejon\(^1,7\), George M. Warimwe\(^1,7\)

\(^1\)KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya
\(^2\)Liverpool School of Tropical Medicine, Liverpool, UK
\(^3\)Department of Psychiatry, University of Oxford, Oxford, UK
\(^4\)KEMRI-Centre for Virus Research, Nairobi, Kenya
\(^5\)The Jenner Institute, University of Oxford, Oxford, UK
\(^6\)London School of Hygiene & Tropical Medicine, London, UK
\(^7\)Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, UK

First published: 15 Nov 2019, 4:179
https://doi.org/10.12688/wellcomeopenres.15568.1
Latest published: 15 Nov 2019, 4:179
https://doi.org/10.12688/wellcomeopenres.15568.1

Abstract

Background: Zika virus (ZIKV) was first discovered in East Africa in 1947. ZIKV has caused microcephaly in the Americas, but it is not known whether ZIKV is a cause of microcephaly in East Africa.

Methods: We used surveillance data from 11,061 live births at Kilifi County Hospital in coastal Kenya between January 2012 and October 2016 to identify microcephaly cases and conducted a nested case-control study to determine risk factors for microcephaly. Gestational age at birth was estimated based on antenatal ultrasound scanning (‘Scanned cohort’) or last menstrual period (‘LMP cohort’, including births ≥37 weeks’ gestation only). Controls were newborns with head circumference Z scores between >-2 and ≤2 SD that were compared to microcephaly cases in relation to ZIKV exposure and other maternal and newborn factors.

Results: Of the 11,061 newborns, 214 (1.9%, 95%CI 1.69, 2.21) had microcephaly. Microcephaly prevalence was 1.0% (95%CI 0.64, 1.70, n=1529) and 2.1% (95%CI 1.81, 2.38, n=9532) in the scanned and LMP cohorts, respectively. After excluding babies <2500 g (n=1199) in the LMP cohort the prevalence was 1.1% (95%CI 0.93, 1.39). Microcephaly
showed an association with being born small for gestational age (p<0.001) but not with ZIKV neutralising antibodies (p=0.6) or anti-ZIKV NS1 IgM response (p=0.9). No samples had a ZIKV neutralising antibody titre that was at least fourfold higher than the corresponding dengue virus (DENV) titre. No ZIKV or other flavivirus RNA was detected in cord blood from cases or controls.

Conclusions: Microcephaly was prevalent in coastal Kenya, but does not appear to be related to ZIKV exposure; the ZIKV response observed in our study population was largely due to cross-reactive responses to DENV or other related flaviviruses. Further research into potential causes and the clinical consequences of microcephaly in this population is urgently needed.

Keywords
Congenital microcephaly, Flavivirus, Zika virus
Introduction
The recent Zika virus (ZIKV) epidemic in the Americas has focused attention on microcephaly as a major complication of in-utero infection and a cause of neurodisability in newborns.1 Very little is known about the burden of microcephaly in Africa and, though ZIKV was first discovered in East Africa2 and the Aedes mosquito vector for ZIKV is plentiful, it is not known whether ZIKV is a cause of microcephaly in the region. A cross-sectional survey in 1966-68 found high (52%) ZIKV antibody seroprevalence among children and adults in coastal Kenya (hereafter as the “scanned cohort”), though antibody cross-reactivity between ZIKV and other flaviviruses in circulation such as dengue virus (DENV) and West Nile virus (WNV) makes the interpretation of these data difficult. Several major flavivirus outbreaks have since occurred in the country4–6, with various serosurveys indicating ongoing flavivirus exposure.7–10 Notably, high flavivirus antibody seroprevalence was reported amongst pregnant women sampled in 2002-03 in coastal Kenya but the association with birth outcomes was not determined9.

We previously initiated a perinatal and maternal health research programme in coastal Kenya to identify risk factors for: 1) severe morbidity and mortality in mothers and newborns and 2) preterm and small gestational age (SGA) births in the INTERBIO-21 Study11. As part of these two studies, we took head circumference measurements and demographic and anthropometric data allowing an estimation of: 1) the prevalence of microcephaly in coastal Kenya; 2) its association with maternal and newborn factors, and 3) its association with flavivirus exposure.

Methods
Study population and data collection
This was a population-based, observational, cohort study undertaken at Kilifi County Hospital (KCH) between January 2012 and October 2016. KCH is a rural public county hospital providing comprehensive obstetric care annually to approximately 5,000 women living along the Kenyan coast. All women completed a standardised admission record as part of these two studies: an ongoing clinical surveillance study assessing risk factors for severe morbidity and mortality in mothers and newborns and the INTERBIO-21 Study. This included socio-demographic information, clinical history including antenatal clinic attendance, clinical findings on admission, delivery details, and maternal and newborn anthropometry. Gestational age was determined either by calculating the difference between the date of delivery and the date of the last reported menstrual period (LMP), including only births ≥237 weeks’ gestation (“LMP cohort”); or by a pregnancy dating ultrasound scan done ≤24 weeks’ gestation for a subset of participants enrolled in the INTERBIO-21 Study, which included preterm and term births, referred to hereafter as the “scanned cohort”.

All newborns had anthropometric measurements (i.e. head circumference, weight and length) taken within 48 hours of birth by nurses and fieldworkers trained as part of the INTERBIO-21 Study, which included quarterly refresher training and continual quality control. Anthropometry for the scanned cohort was done in duplicate by two different fieldworkers, and discrepancies resolved by a third measurement.11 Maternal blood for routine and research samples was collected on admission, and umbilical cord blood was collected at delivery. Maternal and cord blood samples were processed, and plasma stored at -80°C, within 24 hours of collection. All mothers provided written informed consent for use of their biological samples and clinical data. The studies were approved by the Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit (KEMRI SERU # 3296 and 1778).

Laboratory procedures
Viral RNA detection. For qRT-PCR detection of ZIKV and other flaviviruses, viral RNA was isolated from cord plasma using the QIAamp® Viral RNA kit (Qiagen) according to manufacturer’s instructions. Samples were then screened for ZIKV and other flavivirus RNA using the Quantitative RT-PCR kit (Qiagen) and published pan-flavivirus (Flavi alls, Flavi all AS2, Flavi all AS4 and Flavi all probe 3 mix) and ZIKV-specific primers and probes, Bonn E and Bonn NS112, on an ABI 7500 Real Time PCR system. Sequences for all primers can be found in the indicated references. The PCR cycling conditions for the pan-flavivirus assay were: 50°C for 20 minutes, 95°C for 15 minutes, followed by 45 cycles comprising 95°C for 15 seconds and 60°C for 1 minute. For ZIKV Bonn E and Bonn NS1 the conditions were: 50°C for 20 minutes, 95°C for 15 minutes, followed by 45 cycles comprising 95°C for 15 seconds and 58°C for 1 minute. A cycle threshold value of ≤40 was used to define positives for all three assays. RNA isolated from ZIKV MR766 strain and a range of other flaviviruses (DENV, WNV and Yellow Fever virus) cultured in Vero E6 cells were used as positive controls, and the PCR mastermix without template used as a negative control in these assays.

FRNT<sub>90</sub> assay. Cord plasma were screened for antibodies to ZIKV using a ZIKV focus reduction neutralisation test (FRNT<sub>90</sub>) and an in-house IgM ELISA assay against ZIKV NS1 antigen strain MR766. For the FRNT<sub>90</sub> assay, heat-inactivated cord plasma samples were diluted to 1:20 in 100 µl Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal calf serum (D10), mixed with an equal volume of D10 containing antigen strain MR766. For the FRNT<sub>90</sub> assay, heat-inactivated cord plasma samples were diluted to 1:20 in 100 µl Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal calf serum (D10), mixed with an equal volume of D10 containing antigen strain MR766. For the FRNT<sub>90</sub> assay, heat-inactivated cord plasma samples were diluted to 1:20 in 100 µl Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal calf serum (D10), mixed with an equal volume of D10 containing antigen strain MR766, and incubated for 1 hour at 37°C. The virus-plasma mixture was then overlaid onto 96-well flat-bottomed plates containing Vero E6 monolayers at 90% confluence for virus adsorption at 37°C, 5% CO<sub>2</sub> for 24 hours. The virus-plasma mixture was aspirated from the wells, 100 µl of D10 was added and the plates incubated for a further 24 hours at 37°C, 5% CO<sub>2</sub>. Immunostaining was then used to detect virus infection. Briefly, cells were gently washed with phosphate buffered saline (PBS), fixed in 4% paraformaldehyde in PBS for 10 minutes and permeabilized with permeabilization buffer (0.5% Triton X-100 in PBS) for 30 minutes. The plates were blocked in Blocker™ Casein (ThermoFisher) before addition of 0.5 µg/ml of the anti-flavivirus E protein monoclonal antibody 4G2 (Native Antigen, UK, Cat. No AbFLAVENV-4G2) in permeabilization buffer for a 2-hour incubation at 37°C. Following a further series of
washes, plates were incubated with a 1:1000 dilution of horse-radish peroxidase (HRP)-conjugated goat anti-mouse IgG antibody (Abcam, Cat. No. ab6789) in permeabilization buffer for 1 hour at 37°C, and colour development of foci done by addition of 3,3’-diaminobenzidine (Sigma) substrate for 10 minutes at room temperature. The plates were finally washed, air dried and foci counted using an AID ELISpot reader. Plasma samples that resulted in at least 90% reduction in foci relative to wells incubated with virus only were considered flavivirus seropositive. Antibody titres against the ZIKV MR766 strain, and against a local DENV-2 isolate obtained from a patient in coastal Kenya, were then estimated for seropositive samples using the FRNT\textsubscript{90} assay on twofold serial plasma dilutions. FRNT\textsubscript{90} antibody titres were calculated using the Reed and Muench method\textsuperscript{14}.

ZIKV NS1 IgM ELISA. For the IgM assay, 96-well flat-bottomed plates were first coated with 1 µg/ml of the ZIKV NS1 antigen (Native Antigen, UK, Cat. No. ZIKV-NS1) at room temperature overnight, then washed in wash buffer (0.05% Tween in PBS) and blocked with Blocker\textsuperscript{TM} Casein (ThermoFisher) for 1 hour. Cord plasma were diluted 1:400 in Blocker\textsuperscript{TM} Casein, added to plates in duplicate and incubated for 2 hours at room temperature. After a further series of washes, a 1:5000 dilution of HRP-conjugated goat anti-human IgM antibody (KPL, Cat. No. 074-1003) in wash buffer was added to plates, incubated for 1 hour, washed and OPD substrate (Sigma) added for colour development for 15 minutes. Plates were read on a Biotek ELISA reader at a wavelength of 492 nm and optical density values for each sample acquired for analysis. Plasma from coastal Kenya residents with previous PCR-confirmed DENV infection\textsuperscript{15} were used as positive controls, while plasma from two European individuals and a pool of cord plasma from 10 neonates without detectable responses to the ZIKV NS1 antigen were used as negative controls. IgM ratios, defined as the ratio between mean sample OD and the mean OD of the negative controls, were then obtained and seropositivity defined as an IgM ratio of >3 as done by others\textsuperscript{16}.

Statistical analysis

Based on World Health Organization recommendations\textsuperscript{14}, microcephaly (cases) was defined as a birth head circumference (HC) Z score < -3 SD from the mean for gestational age and sex using INTERGROWTH-21\textsuperscript{*} (IG21) newborn size reference charts for births <33 weeks’ gestation\textsuperscript{15}, and standards for births ≥33 weeks’ gestation\textsuperscript{16}. Controls were defined as newborns with HC Z scores between > -2 and ≤ 2 SD. Univariable logistic regression models were used to estimate associations between microcephaly and maternal or newborn variables hypothesised to be putative risk factors (22 variables tested; Table 1). A nominal two-sided p value was calculated as <0.002 (i.e. 0.05 divided by 22 for the number of covariates) following

| Covariate         | Categories | n/N cases (%) | Crude OR (95% CI) | P value |
|-------------------|------------|---------------|-------------------|---------|
| Newborn factors   |            |               |                   |         |
| Sex               | Male       | 69/4794 (1.4%)| 1                 |         |
|                   | Female     | 42/4303 (1.0%)| 0.67 (0.46, 0.99) | 0.05    |
| Small for gestational age (SGA) | Normal     | 61/7331 (0.8%)| 1                 |         |
|                   | SGA        | 50/1766 (2.8%)| 3.47 (2.38, 5.07) | <0.001  |
| Type of birth     | Singleton  | 106/8879 (1.2%)| 1                |         |
|                   | Multifetal | 5/218 (2.3%)  | 1.9 (0.80, 4.75)  | 0.14    |
| Year of birth     | 2012       | 17/1381 (1.2%)| 1                |         |
|                   | 2013       | 28/1499 (1.9%)| 1.53 (0.83, 2.80)| 0.17    |
|                   | 2014       | 23/2379 (1.0%)| 0.78 (0.42, 1.47)| 0.45    |
|                   | 2015       | 23/2043 (1.1%)| 0.91 (0.49, 1.72)| 0.78    |
|                   | 2016       | 20/1795 (1.1%)| 0.90 (0.47, 1.73)| 0.76    |
| Season            | January – March | 24/2245 (1.1%)| 1                |         |
|                   | April – June | 41/2742 (1.5%)| 1.40 (0.85, 2.33)| 0.19    |
|                   | July – September | 22/2240 (1.0%)| 0.92 (0.51, 1.64)| 0.77    |
|                   | October – December | 24/1870 (1.3%)| 1.20 (0.68, 2.13)| 0.52    |
| Covariate                          | Categories          | n/N cases (%) | Crude OR (95% CI) | P value |
|-----------------------------------|---------------------|---------------|-------------------|---------|
| **Maternal factors**              |                     |               |                   |         |
| **Sociodemographic factors**      |                     |               |                   |         |
| Maternal age                      | <20 years           | 17/1339 (1.3%)| 1                 |         |
|                                  | 20 to 35 years      | 87/6966 (1.2%)| 0.98 (0.58, 1.66) | 0.95    |
|                                  | >35 years           | 7/783 (0.9%)  | 0.70 (0.29, 1.70) | 0.43    |
| Marital status                    | Married             | 99/8329 (1.2%)| 1                 |         |
|                                  | Unmarried           | 10/665 (1.5%) | 1.27 (0.66, 2.44) | 0.47    |
| Education level                   | Secondary or more   | 21/2627 (0.8%)| 1                 |         |
|                                  | Primary school      | 73/5253 (1.4%)| 1.75 (1.07, 2.85) | 0.02    |
|                                  | None                | 13/1010 (1.3) | 1.62 (0.81, 3.24) | 0.17    |
| Residence                         | Other               | 70/5893 (1.2%)| 1                 |         |
|                                  | Kilifi township     | 41/3176 (1.3%)| 1.09 (0.74, 1.60) | 0.67    |
| Type of house                     | Stone wall          | 45/4702 (1.0%)| 1                 |         |
|                                  | Mud wall            | 63/4328 (1.5%)| 1.53 (1.04, 2.25) | 0.03    |
| Obstetric history                 |                     |               |                   |         |
| Parity                            | Primigravida        | 41/3302 (1.2%)| 1                 |         |
|                                  | Multigravida        | 70/5738 (1.2%)| 0.98 (0.67, 1.45) | 0.93    |
| Antenatal care attendance         | ≥4 visits           | 69/5887 (1.2%)| 1                 |         |
|                                  | 0 to 3 visits       | 42/3434 (1.3%)| 1.05 (0.72, 1.55) | 0.79    |
| Medication during pregnancy       |                     |               |                   |         |
| Folic acid supplements            | Yes                 | 102/8292 (1.2%)| 1                 |         |
|                                  | No                  | 9/795 (1.1%)  | 0.92 (0.46, 1.82) | 0.81    |
| Malaria prophylaxis               | ≥3 doses            | 61/5166 (1.2%)| 1                 |         |
|                                  | 1 to 2 doses        | 47/3070 (1.5%)| 1.30 (0.89, 1.91) | 0.18    |
|                                  | None                | 3/689 (0.4%)  | 0.37 (0.11, 1.17) | 0.09    |
| Tetanus vaccination               | Yes                 | 95/7706 (1.2%)| 1                 |         |
|                                  | No                  | 13/1137 (1.1%)| 0.93 (0.52, 1.66) | 0.80    |
| Maternal co-morbidities and infections |                    |               |                   |         |
| Mid-upper arm circumference (MUAC)| Normal (23–30cm)    | 76/6490 (1.2%)| 1                 |         |
|                                  | Low (<23cm)         | 13/990 (1.3%) | 1.12 (0.62, 2.03) | 0.70    |
|                                  | High (≥30cm)        | 9/997 (0.9%)  | 0.77 (0.38, 1.54) | 0.46    |
| Hypertension in pregnancy*        | No                  | 92/7623 (1.2%)| 1                 |         |
|                                  | Yes                 | 9/540 (1.7%)  | 1.39 (0.70, 2.77) | 0.35    |
| HIV status                        | Negative            | 107/8605 (1.2%)| 1                 |         |
|                                  | Positive            | 5/365 (1.1%)  | 0.88 (0.32, 2.40) | 0.80    |
| Maternal anaemia                  | No                  | 21/2321 (0.9%)| 1                 |         |
|                                  | Yes                 | 66/5436 (1.2%)| 1.35 (0.82, 2.20) | 0.24    |
| VDRL (syphilis test)              | Negative            | 95/8014 (1.2%)| 1                 |         |
|                                  | Positive            | 1/45 (2.2%)   | 1.89 (0.26, 13.89)| 0.53    |
| Other risk exposures              |                     |               |                   |         |
| Substance use                     | No                  | 108/8855 (1.2%)| 1                 |         |
|                                  | Yes                 | 3/232 (1.3%)  | 1.06 (0.33, 3.37) | 0.92    |
| Contact with cattle               | No                  | 101/8225 (1.2%)| 1                 |         |
|                                  | Yes                 | 7/463 (1.5%)  | 1.23 (0.57, 2.67) | 0.59    |
Bonferroni adjustment for multiple testing. Variables reaching the nominal p<0.002 were then included in a multivariable logistic regression model and their adjusted association with microcephaly estimated. All logistic regression analyses were performed using pooled data from the scanned and LMP cohorts, respectively. To assess the distribution of variables between the two cohorts stratified analyses were performed using $\chi^2$ tests (for categorical variables) and Mann-Whitney U-tests (for continuous variables). All analyses were carried out in Stata™ version 15 with two-sided p-values reported.

Results
Prevalence of microcephaly
Between January 2012 and October 2016 there were 21,143 births at KCH. We excluded stillbirths (n=984), consent withdrawals (n=1771), births with missing key variables (sex, gestational age, HC Z scores and birth weight; n=3784) and preterm newborns for the LMP cohort only (n=3543). We included 11061 live births in the main analysis (Figure 1). The mean gestational age of newborns in the scanned cohort was 38.6 weeks (95% CI 38.44, 38.66) and 39.3 weeks (95% CI 39.26, 39.32) for newborns in the LMP cohort.

There was an excess frequency of births with HC Z scores below -3 SD in the study population when compared to the expected normal distribution (Figure 2). However, the observed frequency of births with HC Z scores between -3 and <-2 SD was similar to the expected normal distribution (Figure 2).

A total of 16 (1.0%) of the 1529 newborns in the scanned cohort, and 198 (2.1%) of the 9532 newborns in the LMP cohort had a HC Z score <-3 SD. We hypothesised that the higher case

![Diagram](image-url)  
*Figure 1. Study participants flow diagram.*
prevalence in the LMP cohort was due to the known inaccuracy of LMP in estimating gestational age as compared to ultrasound scans, leading to preterm births being classified as term, in turn resulting in a lower Z score than would have been assigned had the gestational age been known accurately. Indeed, among 1399 births (1253 term, 146 preterm) in the scanned cohort (used as gold standard) that also had corresponding LMP gestation ages, LMP gestation would have misclassified 9.3% (117/1253) of the term births as preterm births, and 39.7% (58/146) of preterms as term births. Therefore, to enhance the specificity of our case definition for associations, we excluded newborns with low birth weight (<2500 g, as per WHO guidelines) from the analysis of the LMP cohort. When this exclusion was applied the prevalence of microcephaly in the LMP cohort was 1.1% (95% CI 0.93, 1.39) among newborns weighing ≥2500 g (n=8333) and 8.6% (95% CI 7.13, 10.32) among those weighing <2500 g (n=1199), a difference that was statistically significant (χ²=286.05, p<0.001; Fig. 2). In contrast, low birth weight showed no association with microcephaly in the scanned cohort (χ²=0.40, p=0.5). All further analyses on the LMP cohort were therefore restricted to newborns weighing ≥2500 g at birth, which when pooled with the scanned cohort gave a case prevalence of 1.1% (95% CI 0.93, 1.35).

Associations between microcephaly and maternal and newborn factors
To identify potential risk factors for microcephaly, we used a nested case-control approach whereby cases (n=111) were compared to controls (newborns with HC Z score > -2 and ≤ 2 SD, n=8986) with respect to various maternal and newborn variables by logistic regression (Table 1 and Table 3). A strong association was observed between microcephaly and being born small for gestational age (SGA), defined as birth weight <10th centile for gestational age and sex on IG21 charts (OR=3.47, 95% CI 2.38, 5.07, p<0.001). Maternal nutritional status, anaemia, HIV status, parity, receipt of interventions provided in the antenatal clinic and all other newborn and maternal factors tested showed no significant association with microcephaly.

Associations between microcephaly and flavivirus exposure
We used qRT-PCR and serological assays to investigate whether flavivirus exposure was associated with microcephaly in our dataset. To test for recent exposure to flavivirus, we measured IgM antibody responses against ZIKV NS1 antigen in cord plasma from 94 cases with available samples and 864 controls matched by year of birth. Overall IgM seropositivity against ZIKV NS1 was 2.4% (95% CI 1.60, 3.59), though this was strongly confounded by cross-reactive responses to DENV since sera from 25 patients from coastal Kenya with lab-confirmed dengue infection were all seropositive on the ZIKV NS1 IgM assay. No association was evident between the ZIKV NS1 IgM response and microcephaly (Table 2). Furthermore, no ZIKV or other flavivirus RNA could be detected in cord plasma from the 94 cases or from a random selection of controls (n=471).

Of the 94 cases with samples available, 71 had sufficient cord plasma material for ZIKV FRNT assay. For the FRNT assay, each of the 71 cases were matched to at least 10 controls by year of birth (n=755). The overall ZIKV FRNT antibody...
Table 2. Associations between flavivirus serology and microcephaly. Prevalence of anti-ZIKV antibody responses as measured by FRNT90 assay and IgM ELISA is shown for cases and controls. Odds ratios, 95% confidence intervals and p value for the association with microcephaly are shown.

| Seropositivity n/N (%) | Crude OR (95% CI) | P |
|------------------------|-------------------|---|
| **ZIKV NS1 IgM assay** |                   |   |
| Controls               | 21/864 (2.4%)     | 1 |
| Cases                  | 2/94 (2.1%)       | 0.87 (0.20, 3.78) | 0.86 |
| **ZIKV FRNT90 assay**  |                   |   |
| Controls               | 61/755 (8.1%)     | 1 |
| Cases                  | 7/71 (9.7%)       | 1.24 (0.55, 2.83) | 0.60 |

Table 3. Stratified analyses estimating associations between microcephaly and maternal and newborn co-factors in each cohort. Univariate analyses assessing the relationship between maternal and newborn factors and microcephaly in each cohort are shown. For each cohort the frequency of cases is shown, and χ² test used for all analyses. When all variables that were statistically significant at p<0.05 in any of the cohorts (indicated by *) were included in a multivariable logistic regression model, only SGA maintained an association with microcephaly (adjusted OR=3.41, 95% CI 2.30, 5.06, p<0.001).

| Covariate | Categories | LMP cohort | | Scanned cohort |
|-----------|------------|------------|-----------------|-----------------|
| **A) Newborn factors** | | | n/N cases (%) | P value | n/N cases (%) | P value |
| Sex       | Male       | 58/4047 (1.4%) | 0.10 | 11/747 (1.5%) | 0.18 |
|           | Female     | 37/3618 (1.0%) |         | 5/685 (0.7%)  |         |
| Small for gestational age (SGA)* | Normal | 51/6184 (0.8%) | <0.001 | 10/1147 (0.9%) | 0.08 |
|           | SGA        | 44/1481 (3.0%) |         | 6/285 (2.1%)  |         |
| Type of birth* | Singleton | 92/7472 (1.2%) | 0.69 | 14/1393 (1.0%) | 0.001 |
|           | Multifetal | 3/193 (1.5%) |         | 2/25 (8.0%)   |         |
| Year of birth | 2012      | 17/1312 (1.3%) | 0.05 | 0/69 (0)      | 0.75 |
|           | 2013      | 25/1225 (2.0%) |         | 3/274 (1.1%)  |         |
|           | 2014      | 14/1712 (0.8%) |         | 9/667 (1.3%)  |         |
|           | 2015      | 19/1621 (1.2%) |         | 4/422 (0.9%)  |         |
|           | 2016      | 20/1795 (1.1%) |         | No data       |         |
| Season | January - March | 21/1835 (1.1%) | 0.33 | 3/410 (0.7%)  | 0.18 |
|          | April - June | 34/2379 (1.4%) |         | 7/363 (1.9%)  |         |
|          | July - September | 17/1899 (0.9%) |         | 5/341 (1.5%)  |         |
|          | October - December | 23/1552 (1.5%) |         | 1/318 (0.3%)  |         |
| **B) Maternal factors** | | | | |
| **Sociodemographic factors** | | | |
| Maternal age | <20 years | 14/1164 (1.2%) | 0.49 | 3/175 (1.7%) | 0.59 |
|           | 20 to 35 years | 76/5835 (1.3%) |         | 11/1131 (1.0%) | 0.95 |
|           | >35 years | 5/659 (0.7%) |         | 2/124 (1.6%)  |         |
| Marital status* | Married | 87/6999 (1.2%) | 0.66 | 12/1330 (0.9%) | 0.002 |
|           | Unmarried | 6/575 (1.2%) |         | 4/90 (4.4%)   |         |
| Education level | Secondary or more | 20/2221 (0.9%) | 0.22 | 1/406 (0.2%)  | 0.15 |
|           | Primary school | 62/4443 (1.4%) |         | 11/810 (1.4%) |         |
|           | None | 10/832 (1.2%) |         | 3/178 (1.7%)  |         |
| Residence | Other | 60/5293 (1.1%) | 0.19 | 10/600 (1.7%) | 0.09 |
|           | Kilifi township | 35/2346 (1.5%) |         | 6/830 (0.7%)  |         |
| Covariate            | Categories    | LMP cohort n/N cases (%) | P value | Scanned cohort n/N cases (%) | P value |
|----------------------|---------------|--------------------------|---------|-----------------------------|---------|
| **Type of house**    | Stone wall    | 36/3902 (0.9%)           | 0.02    | 9/800 (1.1%)                | 0.99    |
|                      | Mud wall      | 56/3708 (1.5%)           |         | 7/620 (1.1%)                |         |
| **Obstetric history**| Primigravida  | 39/2814 (1.4%)           | 0.40    | 2/488 (0.4%)                | 0.06    |
|                      | Multigravida  | 56/4812 (1.2%)           |         | 14/926 (1.5%)               |         |
| **Antenatal care**   | ≥4 visits     | 57/4501 (1.3%)           | 0.87    | 12/1221 (1.0%)              | 0.22    |
|                      | 0 to 3 visits | 38/3102 (1.2%)           |         | 4/203 (2.0%)                |         |
| **Medication during pregnancy** | Yes | 86/6947 (1.2%) | 0.95 | 16/1345 (1.2%) | 0.32 |
|                      | No            | 9/713 (1.3%)             |         | 0/82 (0)                    |         |
| **Malaria prophylaxis** | ≥3 doses     | 53/4106 (1.3%)           | 0.07    | 8/1060 (0.7%)               | 0.05    |
|                      | 1 to 2 doses  | 40/2785 (1.4%)           |         | 7/285 (2.5%)                |         |
|                      | None          | 2/632 (0.3%)             |         | 1/57 (1.7%)                 |         |
| **Tetanus vaccination** | Yes | 79/6456 (1.2%) | 0.82 | 16/1250 (1.3%) | 0.17 |
|                      | No            | 13/994 (1.3%)            |         | 0/143 (0)                   |         |
| **Maternal co-morbidities and infections** | Normal (23-30cm) | 65/5417 (1.2%) | 0.85 | 11/1073 (1.0%) | 0.22 |
|                      | Low (<23cm)   | 9/822 (1.1%)             |         | 4/168 (2.4%)                |         |
|                      | High (≥30cm)  | 8/812 (1.0%)             |         | 1/185 (0.5%)                |         |
| **Hypertension in pregnancy** | No | 77/6296 (1.2%) | 0.31 | 15/1327 (1.1%) | 0.996 |
|                      | Yes           | 8/452 (1.8%)             |         | 1/88 (1.1%)                 |         |
| **HIV status**       | Negative      | 91/7277 (1.1%)           | 0.78    | 16/1328 (1.2%)              | 0.30    |
|                      | Positive      | 4/278 (1.4%)             |         | 0/87 (0)                    |         |
| **Maternal anaemia** | No            | 19/1885 (1.0%)           | 0.46    | 2/436 (0.5%)                | 0.21    |
|                      | Yes           | 56/4570 (1.2%)           |         | 10/866 (1.1%)               |         |
| **VDRL (syphilis test)** | Negative   | 79/6732 (1.2%) | 0.34 | 16/1282 (1.2%) | 0.71 |
|                      | Positive      | 1/34 (2.9%)              |         | 0/11 (0)                    |         |
| **Other risk exposures** | No | 93/7459 (1.2%) | 0.75 | 15/1396 (1.1%) | 0.26 |
|                      | Yes           | 2/201 (1.0%)             |         | 1/31 (3.2%)                 |         |
| **Contact with cattle** | No | 87/6907 (1.3%) | 0.99 | 14/1318 (1.1%) | 0.13 |
|                      | Yes           | 5/399 (1.2%)             |         | 2/64 (3.1%)                 |         |

Prevalence in the study population was 8.2% (95% CI 6.54, 10.32), but this showed no association with microcephaly (Table 2 and Figure 3).

To characterise the ZIKV FRNT90 response further we measured FRNT90 antibody levels of the ZIKV FRNT90 seropositive cord plasma (7 cases, 61 controls) against a local DENV-2 isolate and compared these to the corresponding ZIKV FRNT90 titres. All ZIKV seropositive samples had antibody against DENV, with DENV FRNT90 titres for most samples (43 of the 68 ZIKV seropositive samples) being at least fourfold higher than the corresponding ZIKV FRNT90 titres (Figure 3). No sample had a ZIKV FRNT90 titre that was at least fourfold higher than that for DENV suggesting that the ZIKV response observed in our study population was largely due to cross-reactive responses to DENV or other related flaviviruses. Raw data used in these analyses are available as Underlying data.

**Discussion**

This study set out to estimate the prevalence of microcephaly in coastal Kenya in a cohort of babies born in a rural public county hospital using data from two prospective studies that...
estimated gestational age clinically and using ultrasound, respectively. We then sought to identify risk factors for microcephaly using a nested case-control design. We found a prevalence of 1 to 2%, which given the 0.1% expected prevalence (<3 SD in the reference populations) suggests a high, previously unrecognized burden of microcephaly in this region. Using logistic regression we found that newborns with microcephaly were more likely to be born SGA. Finally, we did not detect any ZIKV or flavivirus RNA among cases or controls; nor differences in anti-ZIKV antibody responses between cases and controls.

A similarly high prevalence of microcephaly has been observed in Nigeria where approximately 1.9% of infants had a HC Z score <3 SD. In comparison, the average pre-ZIKV epidemic prevalence of microcephaly in 55 hospitals in the Americas was estimated at 0.04% (95% CI 0.041, 0.049), while the prevalence among 24 European Surveillance of Congenital Anomalies registries ranged between 0.004% and 0.04%. During the ZIKV epidemic the overall microcephaly prevalence (HC Z score <3 SD) in Pernambuco, one of the most severely affected states in Brazil, was estimated at 0.15% (95% CI 0.12, 0.17), almost ten times lower than that observed in our dataset.

Definitions of microcephaly are complex and confounded by prematurity. Could we have overestimated the prevalence? We showed that use of the LMP led to an overestimate of gestational age compared with the gold-standard method of ultrasound. It is possible that we missed the viraemia in cord blood as a result of infection occurring earlier in pregnancy, as is common for ZIKV-associated microcephaly. Sample collection in this study was only done at the time of delivery. However, if ZIKV was a significant cause of microcephaly we would expect an increase in IgM levels to ZIKV in cord blood, as reported elsewhere among children with microcephaly secondary to ZIKV.

It is possible that we missed the viraemia in cord blood as a result of infection occurring earlier in pregnancy, as is common for ZIKV-associated microcephaly. Sample collection in this study was only done at the time of delivery. However, if ZIKV was a significant cause of microcephaly we would expect an increase in IgM levels to ZIKV in cord blood, as reported elsewhere among children with microcephaly secondary to ZIKV.

We undertook detailed serological testing in cases and controls and did not find any ZIKV or flavivirus RNA. In addition, we showed no differences in anti-ZIKV FRNT90 or IgM antibody response between cases and controls. Notably, all the ZIKV FRNT90 seropositive samples were also seropositive for DENV. Comparison of FRNT90 titres is conventionally used to infer specific flavivirus exposure; if the detected responses were due to recent ZIKV exposure we would expect ZIKV FRNT90 titres to be at least fourfold higher than the DENV FRNT90 titres in the corresponding sample(s). However, no sample had a ZIKV FRNT90 titre that was fourfold higher than the corresponding DENV FRNT90 titre. In fact, for more than half (63%) of the seropositive samples DENV FRNT90 titres were at least fourfold higher than ZIKV FRNT90 titres. Furthermore, the lack of seasonality in the risk of microcephaly, lack of trend by calendar year, and absence of any difference by urban/rural residence suggest it is unlikely that a vector borne or respiratory infection, including ZIKV, is the cause of microcephaly in our setting. The only strongly significant risk factor for microcephaly in our population was SGA; this sub-group accounted for 45% of all cases.

Definitions of microcephaly are complex and confounded by prematurity. Could we have overestimated the prevalence? We showed that use of the LMP led to an overestimate of gestational age compared with the gold-standard method of ultrasound.

We undertook detailed serological testing in cases and controls and did not find any ZIKV or flavivirus RNA. In addition, we showed no differences in anti-ZIKV FRNT90 or IgM antibody response between cases and controls. Notably, all the ZIKV FRNT90 seropositive samples were also seropositive for DENV. Comparison of FRNT90 titres is conventionally used to infer specific flavivirus exposure; if the detected responses were due to recent ZIKV exposure we would expect ZIKV FRNT90 titres to be at least fourfold higher than the DENV FRNT90 titres in the corresponding sample(s). However, no sample had a ZIKV FRNT90 titre that was fourfold higher than the corresponding DENV FRNT90 titre. In fact, for more than half (63%) of the seropositive samples DENV FRNT90 titres were at least fourfold higher than ZIKV FRNT90 titres. Furthermore, the lack of seasonality in the risk of microcephaly, lack of trend by calendar year, and absence of any difference by urban/rural residence suggest it is unlikely that a vector borne or respiratory infection, including ZIKV, is the cause of microcephaly in our setting. The only strongly significant risk factor for microcephaly in our population was SGA; this sub-group accounted for 45% of all cases.

It is possible that we missed the viraemia in cord blood as a result of infection occurring earlier in pregnancy, as is common for ZIKV-associated microcephaly. Sample collection in this study was only done at the time of delivery. However, if ZIKV was a significant cause of microcephaly we would expect an increase in IgM levels to ZIKV in cord blood, as reported elsewhere among children with microcephaly secondary to ZIKV.

Furthermore, although molecular evidence of infection is not common among newborns with ZIKV-induced microcephaly, we would expect at least some to have prolonged ZIKV viraemia if this were a common cause. The complete absence of any molecular evidence of ZIKV in cases and controls, including in newborns with measurable cord blood anti-ZIKV FRNT90 and IgM antibody responses, leads us to believe that the anti-ZIKV response detected in our study is cross-reactive to other flaviviruses. This hypothesis is supported by the high seroprevalence of DENV antibodies measured FRNT90 in this study and by other methods in previous studies in coastal Kenya, including genetic, nutritional and environmental factors, also warrant further investigation and may underlie the associations observed.
between microcephaly and SGA newborns (as observed by others). In addition to using LMP in a subgroup to define gestational age, this study had other limitations. The study population only included births at KCH, and hence will have missed births occurring at home or in other local health facilities. However, we have important data from our uniquely detailed demographic surveillance system which indicates that approximately 40% of all births in the hospital catchment area occur at KCH.

This study has allowed the first estimation of the risk of congenital microcephaly in coastal Kenya. A 1-2% prevalence of microcephaly may impose a public health burden depending on the clinical outcomes associated. Future prospective studies to characterise and determine post-discharge mortality, neurocognitive outcomes and aetiology of microcephaly in the region are a priority.

**Data availability**

**Underlying data**

Harvard Dataverse: Replication Data for: Congenital Microcephaly Unrelated to Flavivirus Exposure in Coastal Kenya. https://doi.org/10.7910/DVN/4EB9PG.

This project contains the following underlying data:

- microcephaly_dataverse_v1 (dataset containing demographic information, anthropometric measures and results of lab assays for participants included in the study).
- GWarimwe_Microcephaly_Codebook (contains variable description and value labels).

**Extended data**

Harvard Dataverse: Replication Data for: Congenital Microcephaly Unrelated to Flavivirus Exposure in Coastal Kenya. https://doi.org/10.7910/DVN/4EB9PG.

This project contains the following extended data:

- GWarimwe_Microcephaly_missing_data_summary (summary of missing data for analysed variables).
- GWarimwe_Microcephaly_readme (readme file).
- microcephaly_dataverse_final (STATA analysis code used for data analysis presented in this article).

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

**Acknowledgements**

We are grateful to Grieven Otieno and Mark Otieno for help with data management and sample access, and to the KIPMAT team for participant recruitment and evaluation. We are grateful to the INTERBIO-21 Study coordination team for training, assessment and monitoring of ultrasound scanning and newborn anthropometry.

**References**

1. Petersen LR, Jamieson DJ, Powers AM, et al.: Zika Virus. N Engl J Med. 2016; 374(16): 1562–63. PubMed Abstract | Publisher Full Text
2. Dick GW. Zika virus. II. Pathogenicity and physical properties. Trans R Soc Trop Med Hyg. 1952; 46(5): 521–34. PubMed Abstract | Publisher Full Text
3. Geser A, Henderson BE, Christensen S: A multipurpose serological survey in Kenya. 2. Results of arbovirus serological tests. Bull World Health Organ. 1970; 43(4): 539–52. PubMed Abstract | Free Full Text
4. Johnson BK, Musoke S, Ochong D, et al.: Dengue-2 virus in Kenya. Lancet. 1982; 2(8291): 208–9. PubMed Abstract | Publisher Full Text
5. Vu DM, Mutsi N, Heath CJ, et al.: Unrecognized Dengue Virus Infections in Children, Western Kenya, 2014-2015. Emerg Infect Dis. 2017; 23(11): 1915–7. PubMed Abstract | Publisher Full Text | Free Full Text
6. Ellis BR, Barrett AD: The enigma of yellow fever in East Africa. Rev Med Virol. 2008; 18(5): 331–46. PubMed Abstract | Publisher Full Text
7. Mease LE, Coldren RL, Musila LA, et al.: Seroprevalence and distribution of arboviral infections among rural Kenyan adults: a cross-sectional study. Viral J 2011; 8: 371. PubMed Abstract | Publisher Full Text | Free Full Text
8. Ochong C, Ahenda P, Vittor AY, et al.: Seroprevalence of Infections with Dengue, Rift Valley Fever and Chikungunya Viruses in Kenya, 2007. PLoS One. 2015; 10(7): e0132645. PubMed Abstract | Publisher Full Text | Free Full Text
9. Sutherland LJ, Cash AA, Huang YJ, et al.: Serologic evidence of arboviral infections among humans in Kenya. Am J Trop Med Hyg. 2011; 85(1): 158–61. PubMed Abstract | Publisher Full Text | Free Full Text
10. Seale AC, Barssosio HC, Koech AC, et al.: Embedding surveillance into clinical care to detect serious adverse events in pregnancy. Vaccine. 2015; 33(47): 6466–8. PubMed Abstract | Publisher Full Text | Free Full Text
11. Kennedy SH, Victor CG, Crick R, et al.: Deep clinical and biological phenotyping of the preterm birth and small for gestational age syndromes: The INTERBIO-21st Newborn Case-Control Study protocol (version 2; peer review: 2 approved). Gates Open Res. 2019; 2: 49. PubMed Abstract | Publisher Full Text | Free Full Text
12. Patel P, Landt O, Kaiser M, et al.: Development of one-step quantitative reverse transcription PCR for the rapid detection of flaviviruses. Virol J. 2013; 10: 58. PubMed Abstract | Publisher Full Text | Free Full Text
13. Corman VM, Rasche A, Baroni C, et al.: Assay optimization for molecular detection of Zika virus. Bull World Health Organ. 2016; 94(12): 880–92. PubMed Abstract | Publisher Full Text | Free Full Text
14. WHO/ZIKV/MOC/163/Rev3. 2016. Reference Source
15. Villar J, Giuliani F, Fenton TR, et al.: INTERGROWTH-21st very preterm size at birth reference charts. Lancet. 2016; 387(10021): 844–5. PubMed Abstract | Publisher Full Text
16. Villar J, Chishik Ismail L, Victor CG, et al.: International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet. 2014; 384(9946): 857–68. PubMed Abstract | Publisher Full Text | Free Full Text
17. Ngoi CN, Price MA, Fields B, et al.: Dengue and Chikungunya Virus Infections among Young Febrile Adults Evaluated for Acute HIV-1 Infection in Coastal Kenya. PLoS One. 2016; 11(12): e0167508. PubMed Abstract | Publisher Full Text | Free Full Text
18. Kamau E, Agoti CN, Ngoi JM, et al.: Complete Genome Sequences of Dengue Virus Type 2 Strains from Kilifi, Kenya. Microbiol Resour Announc. 2019; 8(4):
19. Barsosio HC, Gitonga JN, Karanja HK: Replication Data for: Congenital Microcephaly Unrelated to Flavivirus Exposure in Coastal Kenya. Harvard Dataverse, V2. 2019. http://www.doi.org/10.7910/DVN4EB9PG

20. Olusanya BO: Full-term newborns with congenital microcephaly and macrocephaly in Southwest Nigeria. Int Health. 2012; 4(2): 128–34. PubMed Abstract | Publisher Full Text

21. Orioli IM, Dolk H, Lopez-Camelo JS, et al.: Prevalence and clinical profile of microcephaly in South America pre-Zika, 2005-14: prevalence and case-control study. BMJ. 2017; 359: i018. PubMed Abstract | Publisher Full Text | Free Full Text

22. Morris JK, Rankin J, Garne E, et al.: Prevalence of microcephaly in Europe: population based study. BMJ. 2016; 354: i4721. PubMed Abstract | Publisher Full Text | Free Full Text

23. Kiebler de Oliveira W, Cortez-escalante J, De Oliveira WT, et al.: Increase in Reported Prevalence of Microcephaly in Infants Born to Women Living in Areas with Confirmed Zika Virus Transmission During the First Trimester of Pregnancy - Brazil, 2015. MMWR Morb Mortal Wkly Rep. 2016; 65(9): 242–7. PubMed Abstract | Publisher Full Text

24. World Health Organization: Laboratory testing for Zika virus infection. WHO/ ZIKV/LAB/161. 2016. Reference Source

25. Cauchemez S, Besnard M, Bompard P, et al.: Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet. 2016; 387(10033): 2125–32. PubMed Abstract | Publisher Full Text | Free Full Text

26. Cordeiro MT, Pena LJ, Brito CA, et al.: Positive IgM for Zika virus in the cerebrospinal fluid of 30 neonates with microcephaly in Brazil. Lancet. 2016; 387(10030): 1811–2. PubMed Abstract | Publisher Full Text

27. Cordeiro MT, Brito CA, Pena LJ, et al.: Results of a Zika Virus (ZIKV) Immunoglobulin M-Specific Diagnostic Assay Are Highly Correlated With Detection of Neutralizing Anti-ZIKV Antibodies in Neonates With Congenital Disease. J Infect Dis. 2016; 214(12): 1897–904. PubMed Abstract | Publisher Full Text

28. Lanciotti RG, Kosoy OL, Laven JJ, et al.: Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg Infect Dis. 2008; 14(8): 1232–9. PubMed Abstract | Publisher Full Text | Free Full Text

29. de Araújo TVB, Ximenes RAA, Miranda-Filho DB, et al.: Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study. Lancet Infect Dis. 2018; 18(3): 328–36. PubMed Abstract | Publisher Full Text

30. Geser A, Christensen S, Thorup I: A multipurpose serological survey in Kenya. 1. Survey methods and progress of field work. Bull World Health Organ. 1970; 43(4): 521–37. PubMed Abstract | Free Full Text

31. Devakumar D, Bampton A, Ferreira MU, et al.: Infectious causes of microcephaly: epidemiology, pathogenesis, diagnosis, and management. Lancet Infect Dis. 2018; 18(1): e1–e13. PubMed Abstract | Publisher Full Text

32. Nawathe A, Doherty J, Pandya P: Fetal microcephaly. BMJ. 2018; 361: k2232. PubMed Abstract | Publisher Full Text
Barsosio et al. have started to address in this paper a gap in the knowledge of both microcephaly and Zika virus in Africa. They investigate the prevalence of microcephaly in a coastal Kenyan population, its association with a range of maternal and newborn factors, whether Zika is circulating in this population, and, if so, whether there is evidence that Zika is causing microcephaly.

The data used for this study were not specifically designed to answer these questions, but the authors try to address the data quality problems as well as possible.

The accuracy of classification of babies at birth as microcephalic or not depends on both accuracy of estimation of gestational age and of head circumference. The authors concentrate on the former source of inaccuracy, but it would be interesting to know also (if the data were recorded) the extent of discordant head circumferences in the smaller "scanned cohort" where duplicate measures were made. In addition, it would be informative to add a Figure showing the head circumferences and gestational ages of the cases <-3SD (classified as microcephaly) in the scanned cohort, shown against the Intergrowth chart.

In clinical practice, one would not expect a clinical diagnosis of microcephaly to be made without further neonatal measurements (including making sure any head molding at birth has resolved), so a degree of misclassification will inevitably remain, with a possible impact on the estimated prevalence, and diluting associations with risk factors.

The microcephaly prevalence (<3SD below the mean) is very high at 1% compared to other published estimates. Follow-up of these babies into childhood to measure their developmental outcomes, as well as brain imaging, is therefore important, as recommended by the authors.

It would be helpful if the authors could add some further details to the Methods and Results. Can
the authors confirm that none of the microcephaly cases had other major malformations or syndromes? Is it possible that there was selective referral of high risk mothers to KCH? What evidence is there that congenital rubella or CMV might be causal factors in this population?

The study could not confirm circulating Zika in this area of Kenya. In the absence of Zika, it could not be a causal factor for microcephaly. The authors point out that ZIKV was first discovered in East Africa, and the Aedes Aegypti mosquito vector is present in Africa. However, the African strain of ZIKV shows different potential for pathogenesis in pregnancy from the Asian/American strain (WHO 2019), and the African mosquito also has a different transmission potential (Aubry et al. 2018), so it should not be assumed that the characteristics of ZIKV as experienced in Latin America would be found in Africa.

References
1. World Health Organisation: Zika Epidemiology Update. 2019. Reference Source
2. Aubry F, Martynow D, Baidaliuk A, Merkling S, et al.: Worldwide survey reveals lower susceptibility of AfricanAedes aegypti mosquitoes to diverse strains of Zika virus. bioRxiv. 2018. Publisher Full Text

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Partly

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Perinatal epidemiology.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 24 February 2020

https://doi.org/10.21956/wellcomeopenres.17049.r37999
Jan Felix Drexler
Institute of Virology, Charité-Universitätsmedizin Berlin, corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Thomas Jaenisch
Colorado School of Public Health, Aurora, CO, USA

Jan Felix Drexler
In the manuscript “Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya” Barsosio and colleagues show their results of an extensive study on the potential role of congenital Zika virus (ZIKV) infections as a cause for microcephaly in Kenya. Although the number of microcephaly cases was high compared to other studies, ZIKV infections were not associated. The study provides very important information about the current role of ZIKV as a teratogenic agent in Africa, where the virus is widespread but reports about congenital malformations due to maternal ZIKV infections are scarce or absent. The size of the sample and the study design are a very good basis for well-founded scientific findings. There are some limitations regarding testing that should be addressed. In general, while Zika infection is not supported by the authors’ results, it cannot be ruled out due to the diagnostic limitations inherent to endemic settings. This should be reflected in the text throughout.

1. ZIKV-specific IgM detection was done by an in-house IgM ELISA assay against the ZIKV NS1 antigen of the prototype strain MR766. It is hard to judge the diagnostic performance of this in-house assay in this particular population and thus the robustness of the authors’ main laboratory findings. Those data must be provided in comparison to other assays. Notably, IgM detection for ZIKV diagnostics suffers from low sensitivity, particularly when targeting NS1-specific antibodies. Combining detection of IgM/IgA antibodies and of antibodies targeting the ZIKV envelope protein would likely increase sensitivity and thus strengthen the findings of the study.

2. The authors describe how ZIKV FRNT90 assays were conducted. The authors should add a technical description on how FRNT90 was done for dengue virus. In the same line of thought, choice of cell lines and virus stocks differing in the ratio of infectious to non-infectious particles (that still bind antibodies) can dramatically affect NT titers. Comparison of titers is thus always challenging in an endemic scenario in which people get infected multiple times with different flaviviruses. Because conserved epitopes among those multiple flaviviruses cross-stimulate anti-flaviviral immune responses and because different flaviviruses may elicit distinct antibody titer magnitudes, comparison of Zika and dengue NTs in this study deserves to be taken with caution. I agree that since dengue titers were consistently above Zika titers, the NTs are not supportive of Zika infection. I would be cautious though to state that they rule out the latter. In an endemic setting, a higher titer against dengue viruses, likely infecting a person multiple times due to the different co-circulating serotypes, does not rule out a Zika infection eliciting a relatively weaker titer. Solutions in patient diagnostics include testing of consecutive sera from acute and convalescence phases of infection, which is not feasible in this study. Can you compare titers in younger (likely less cumulative flavivirus infections) and older participants?
3. Only cord blood was tested. The authors should perform serologic testing of the mothers for ZIKV-specific IgG. Their-case control design should allow detecting potential ZIKV-specific differences in overall maternal exposure and height of ZIKV-specific neutralizing antibody titers as indirect evidence of potential congenital infection.\textsuperscript{4,5}

4. As discussed by the authors, the rate of microcephaly was exceptionally high in this study. If not ZIKV, then what is the cause? Both molecular and serologic tests for other pathogens commonly linked to congenital malformations are readily available, including toxoplasmosis, syphilis, rubella virus or herpesviruses.\textsuperscript{6} Confirmation of another aetiology would strengthen the apparent lack of ZIKV.

\textit{Thomas Jaenisch}

The manuscript provides useful and much needed data about the frequency of microcephaly in Africa, specifically in coastal Kenya, in the absence of ZIKV transmission. It would be great if the authors could provide even more detailed information about the distribution of head circumference in the cohorts they have followed.

The manuscript should be edited before indexing:

**Title:**
The potential link to ZIKV infections or flavivirus exposure in the title is misleading, which should be clarified. The authors report that very likely there was no ZIKV transmission during the observation period. The current title leaves room for interpretation in the direction that the microcephaly observed in coastal Kenya is not associated to ZIKV infections, which were present in the region.

The second weakness of the title is that the authors do not mention ZIKV infection directly in the title (even if ZIKV is the only flavivirus known to cause congenital abnormalities or microcephaly) because the serological results presented to not allow to make this statement.

**Abstract – conclusions:**
“Microcephaly was prevalent in coastal Kenya, but does not appear to be related to ZIKV exposure...”

Same problem as above with the title. The authors continue in the next sentence with “... the ZIKV response observed in our study population was largely due to cross-reactive responses to DENV or other related flaviviruses”. However, this still leaves room for interpretation. The most likely scenario here is that there was simply no ZIKV transmission during the observation period.

**Methods – statistical analysis**
5\textsuperscript{th} line of statistical analysis: there seems to be a word missing “... using INTERGROWTH-21\textsuperscript{ST} (I21) newborn size-reference charts ......, and standards for birth...”. Which standards?

The authors chose to compare microcephaly < 3SD (cases) with -2SD to +2SD (controls). Why did they not choose -1SD to +1SD, which would still have resulted in a big enough N for the controls? The reason for this question is that it currently is not clear how many ‘controls’ are close to -2SD (just above the cut-off) and could actually be counted as microcephaly or at least borderline according to some definitions.

This reviewer thinks that this warrants a sensitivity analysis with the definition of -1SD - +1SD for controls.
Results and Figures
In Figure 1, all study participants should be accounted for. However, we lack the number of the babies born with the head circumference between -3SD and -2SD (and potentially plus 3SD). Please include this in a footnote to the figure.

Figure 2 is important to understand the distribution of head circumference in the cohorts, and within different sub-populations. Please include the ‘-1 to +1’ category. In addition, it would be interesting to include a histogram with the actual distribution of head circumference according to SD to really see the spread, and if the distribution approximates a normal distribution or not.

Discussion
The authors stratified the results according to the ascertainment of gestational age – ‘scanned’ versus ‘last menstrual period’. It is interesting to see the effect size of the potential biases resulting from the different methods and this reviewer would encourage the authors to extend the discussion around this point.

References
1. Bozza FA, Moreira-Soto A, Rockstroh A, Fischer C, et al.: Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil. *Emerg Infect Dis*. 25 (2): 311-315 PubMed Abstract | Publisher Full Text
2. Warnecke JM, Lattwein E, Saschenbrecker S, Stöcker W, et al.: Added value of IgA antibodies against Zika virus non-structural protein 1 in the diagnosis of acute Zika virus infections. *J Virol Methods*. 267: 8-15 PubMed Abstract | Publisher Full Text
3. Kikuti M, Tauro L, Moreira P, Campos G, et al.: Diagnostic performance of commercial IgM and IgG enzyme-linked immunoassays (ELISAs) for diagnosis of Zika virus infection. *Virology Journal*. 2018; 15 (1). Publisher Full Text
4. Moreira-Soto A, Sarno M, Pedroso C, Netto E, et al.: Evidence for Congenital Zika Virus Infection From Neutralizing Antibody Titers in Maternal Sera, Northeastern Brazil. *The Journal of Infectious Diseases*. 2017; 216 (12): 1501-1504 Publisher Full Text
5. Robbiani DF, Olsen PC, Costa F, Wang Q, et al.: Risk of Zika microcephaly correlates with features of maternal antibodies. *J Exp Med*. 2019; 216 (10): 2302-2315 PubMed Abstract | Publisher Full Text
6. Stegmann BJ, Carey JC: TORCH Infections. Toxoplasmosis, Other (syphilis, varicella-zoster, parvovirus B19), Rubella, Cytomegalovirus (CMV), and Herpes infections. *Curr Womens Health Rep*. 2002; 2 (4): 253-8 PubMed Abstract

Is the work clearly and accurately presented and does it cite the current literature?
Partly

Is the study design appropriate and is the work technically sound?
Partly

Are sufficient details of methods and analysis provided to allow replication by others?
No

If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable

Are all the source data underlying the results available to ensure full reproducibility?
No

Are the conclusions drawn adequately supported by the results?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Diagnostics of emerging viruses.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Reviewer Report 07 February 2020

https://doi.org/10.21956/wellcomeopenres.17049.r37617

© 2020 Schuler-Faccini L. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lavinia Schuler-Faccini
Postgraduate Program in Genetics and Molecular Biology, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil

This is a manuscript analyzing the prevalence of microcephaly at birth in Coastal Kenya and whether ZIKV could have a role in the etiology of the cases of microcephaly. The authors used data from 11,061 newborns from a County Hospital from 2012 to 2016. They observed a high prevalence of 1% of microcephaly (defined as HC Z-score <3 SD from the mean for GA and sex) in scanned pregnancies. ZIKV was not identified as one of the causes and the only covariate significantly associated was SGA. The authors discuss the limitations of their work but the high prevalence of severe microcephaly is most probably real. Therefore this is an important manuscript to be indexed, and I agree with the authors in their conclusion that further research into potential causes and the clinical consequences of microcephaly in this population is urgently needed.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

**Are all the source data underlying the results available to ensure full reproducibility?**
Yes

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Medical genetics, dysmorphology, teratogenesis.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.